Compare Adaptive Biotechnologies Corp (ADPT) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Cytokinetics Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Cytokinetics Inc trades at $84.75 (market cap $11.62B). The key difference: Cytokinetics Inc is far larger — about 3.5× Adaptive Biotechnologies Corp's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | CYTK | |
|---|---|---|
Market Cap | $3.33B | $11.62B |
Sector | Health | Technology |
52-Week High | $22.37 | $87.26 |
52-Week Low | $10.24 | $33.23 |
Enterprise Value | $3.19B | $12.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CYTK trades at $85.57, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported a net loss of $784.96 million in 2025, with revenue of $88.04 million, but recent news highlights the European launch of MYQORZO and upcoming clinical data presentations at the ESC Congress 2026, indicating growth potential.
The outlook for CYTK is driven by product launches and clinical milestones, but high valuation (P/S 98.09) and persistent losses pose risks. Analyst consensus is overwhelmingly bullish with a $110.60 price target, though investors must weigh the speculative nature against execution risks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
